Profile change history

What changed for Elamipretide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Elamipretide identity.

56Total events
51Record additions
5Version changes
8Cited source years

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT07531251

ClinicalTrials.gov posted a newer version of NCT07531251, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.

Cited source date

Before
2026-07-13
After
2026-11-09

Source observed date

Before
2026-08-10
After
2026-11-15

Cited source records

Before
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
After
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

Headline citations

Before
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
After
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

Summary citations

Before
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f
After
ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2]

Source snapshot commitment

Before
cd18ee2b24e957403e6fb8e09ac12d4bfc61572774f57546d541ffda74c3fb1f
After
b1b09dfd129e96bca737737861669ba793549d2ec86352284d46bfaf2b7b5c0d
Profile status changed

Elamipretide profile

We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
U.S. accelerated approval for a specified Barth syndrome population
After
FDA-approved as Forzinity under accelerated approval for Barth syndrome

Profile summary

Before
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
After
A mitochondria-targeting peptide that FDA granted accelerated approval as Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg.

Evidence note

Before
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.
After
The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.

Cited source records

Before
ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025
After
ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025, federal-register-2024-20062-66035b025ae4

Named organizations

Before
Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]
After
Stealth BioTherapeutics Inc. [sources: ctg-nct07531251-v4]; U.S. Food and Drug Administration [sources: fda-forzinity-approval-2025]

Claim citations

Before
name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025; summary: fda-forzinity-approval-2025; evidenceNote: fda-forzinity-approval-2025
After
name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025, fda-forzinity-label-2025; summary: fda-forzinity-approval-2025, fda-forzinity-label-2025; evidenceNote: fda-forzinity-label-2025, fda-forzinity-approval-2025
Correction

Elamipretide profile

The previous profile described elamipretide only as investigational. We added FDA's September 19, 2025 accelerated approval of Forzinity for the specified Barth syndrome population. This correction does not extend that approval to other uses or formulations.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Status

Before
Investigational
After
U.S. accelerated approval for a specified Barth syndrome population

Status classification

Before
investigational
After
approved

Profile summary

Before
A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
After
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.

Evidence note

Before
ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.
After
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.

Related names

Before
SS-31, MTP-131
After
SS-31, MTP-131, Forzinity

Cited source records

Before
ctg-nct07531251-v4
After
ctg-nct07531251-v4, fda-forzinity-approval-2025

Claim citations

Before
name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4; category: ctg-nct07531251-v4; status: ctg-nct07531251-v4; summary: ctg-nct07531251-v4; evidenceNote: ctg-nct07531251-v4
After
name: ctg-nct07531251-v4; aliases: ctg-nct07531251-v4, fda-forzinity-approval-2025; category: ctg-nct07531251-v4; status: fda-forzinity-approval-2025; summary: fda-forzinity-approval-2025; evidenceNote: fda-forzinity-approval-2025
Correction

Elamipretide profile

We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Cited source records

Before
ctg-nct07531251-v4, fda-forzinity-approval-2025
After
ctg-nct07531251-v4, fda-forzinity-approval-2025, fda-forzinity-label-2025
Profile updated

Elamipretide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A mitochondria-targeting peptide candidate represented in ClinicalTrials.gov.
After
A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.

Collection chronology

Evidence added to PeptideScanner

Browse all 51 connected records →

Showing the latest 51 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

ClinicalTrials.gov record NCT07927972

PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02693119

PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
September 9, 2026
Cited source date
November 30, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03891875

PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
September 9, 2026
Cited source date
July 12, 2024
Evidence lane
Clinical trials
Record added

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

PubMed lists PMID 42708867 in Physiological research as Journal Article, Comparative Study, with publication-date metadata of 2026-08-31 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
September 8, 2026
Evidence lane
Literature metadata
Record added

Federal Register notice 2024-20062

The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

PeptideScanner change date
August 21, 2026
Cited source date
September 6, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 2025-23409

The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

PeptideScanner change date
August 21, 2026
Cited source date
December 19, 2025
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT06373731

PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 14, 2026
Cited source date
May 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07531251

PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 14, 2026
Cited source date
July 13, 2026
Evidence lane
Clinical trials
Record added

The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.

PubMed lists PMID 23813215 in Journal of the American Society of Nephrology : JASN as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.

PubMed lists PMID 29951944 in Cardiovascular drugs and therapy as Journal Article, with publication-date metadata of 2018-08 (month precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
March 12, 2024
Evidence lane
Literature metadata
Record added

A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
August 1, 2024
Evidence lane
Literature metadata
Record added

Mitochondrial protein interaction landscape of SS-31.

PubMed lists PMID 32554501 in Proceedings of the National Academy of Sciences of the United States of America as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
March 30, 2024
Evidence lane
Literature metadata
Record added

Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.

PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 28, 2025
Evidence lane
Literature metadata
Record added

Targeting mitochondrial dysfunction with elamipretide.

PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 28, 2025
Evidence lane
Literature metadata
Record added

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
August 15, 2023
Evidence lane
Literature metadata
Record added

Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice.

PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 19, 2024
Evidence lane
Literature metadata
Record added

Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

PubMed lists PMID 37041653 in Orphanet journal of rare diseases as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.

PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.

PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
December 14, 2024
Evidence lane
Literature metadata
Record added

Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

PubMed lists PMID 39917770 in European heart journal. Case reports as Case Reports, Journal Article, with publication-date metadata of 2025-01-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
February 8, 2025
Evidence lane
Literature metadata
Record added

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
November 18, 2025
Evidence lane
Literature metadata
Record added

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
January 14, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 37268435

PeptideScanner retained PubMed bibliographic metadata for PMID 37268435 at 2026-07-30T16:20:36.524Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-06-02. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
May 18, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 38237649

PeptideScanner retained PubMed bibliographic metadata for PMID 38237649 at 2026-08-10T18:13:32.340Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2024-01-18. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
July 9, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 38602181

PeptideScanner retained PubMed bibliographic metadata for PMID 38602181 at 2026-07-30T16:11:44.832Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
July 1, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 38688894

PeptideScanner retained PubMed bibliographic metadata for PMID 38688894 at 2026-07-30T16:14:06.935Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 27, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 38990651

PeptideScanner retained PubMed bibliographic metadata for PMID 38990651 at 2026-07-30T16:14:08.785Z. PubMed recorded a metadata revision date of 2026-06-01 and an Entrez history date of 2024-07-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 1, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 39574155

PeptideScanner retained PubMed bibliographic metadata for PMID 39574155 at 2026-07-30T16:20:39.074Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-11-22. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
May 19, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 39605874

PeptideScanner retained PubMed bibliographic metadata for PMID 39605874 at 2026-07-30T16:20:39.082Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-11-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
May 18, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 40570323

PeptideScanner retained PubMed bibliographic metadata for PMID 40570323 at 2026-07-30T16:14:11.030Z. PubMed recorded a metadata revision date of 2026-06-17 and an Entrez history date of 2025-06-26. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 17, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41500837

PeptideScanner retained PubMed bibliographic metadata for PMID 41500837 at 2026-07-30T16:14:13.067Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 25, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41596703

PeptideScanner retained PubMed bibliographic metadata for PMID 41596703 at 2026-07-30T16:11:44.884Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
July 1, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41612464

PeptideScanner retained PubMed bibliographic metadata for PMID 41612464 at 2026-07-30T16:14:14.832Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-01-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 27, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41801306

PeptideScanner retained PubMed bibliographic metadata for PMID 41801306 at 2026-08-10T18:13:44.801Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
July 10, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42082001

PeptideScanner retained PubMed bibliographic metadata for PMID 42082001 at 2026-07-30T16:14:16.712Z. PubMed recorded a metadata revision date of 2026-06-12 and an Entrez history date of 2026-05-04. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 12, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42290373

PeptideScanner retained PubMed bibliographic metadata for PMID 42290373 at 2026-07-30T16:14:18.165Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 15, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42291734

PeptideScanner retained PubMed bibliographic metadata for PMID 42291734 at 2026-07-30T16:14:19.224Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
June 15, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42415111

PeptideScanner retained PubMed bibliographic metadata for PMID 42415111 at 2026-08-10T18:13:53.859Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2026-07-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
July 7, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 35611788

PeptideScanner retained PubMed bibliographic metadata for PMID 35611788 at 2026-08-10T18:13:32.311Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2022-05-25. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
July 26, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42219795

PeptideScanner retained PubMed bibliographic metadata for PMID 42219795 at 2026-08-10T18:13:50.715Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
July 17, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42443448

PeptideScanner retained PubMed bibliographic metadata for PMID 42443448 at 2026-08-10T18:13:55.249Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
July 13, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42448476

PeptideScanner retained PubMed bibliographic metadata for PMID 42448476 at 2026-08-10T18:13:55.255Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
July 14, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 17151329

PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 20, 2014
Evidence lane
Literature metadata
Record added

PubMed record PMID 21697135

PeptideScanner retained PubMed bibliographic metadata for PMID 21697135 at 2026-07-30T21:57:00.496Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2011-06-24. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

PubMed record PMID 42450582

PeptideScanner retained PubMed bibliographic metadata for PMID 42450582 at 2026-08-10T18:13:55.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 26, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42456009

PeptideScanner retained PubMed bibliographic metadata for PMID 42456009 at 2026-08-10T18:13:55.284Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 27, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT02788747

PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 9, 2026
Cited source date
May 14, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03098797

PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 9, 2026
Cited source date
April 16, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05162768

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 8, 2026
Cited source date
October 24, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05168774

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.

PeptideScanner change date
August 8, 2026
Cited source date
December 12, 2025
Evidence lane
Clinical trials